Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Non-small cell lung cancer (NSCLC) prognosis is influenced by various factors.
• Identifying reliable prognostic markers is crucial for resectable NSCLC management.

Purpose of the Study:

• To determine the prognostic significance of clinical, cellular, and immunologic markers in patients with resectable NSCLC.
• To correlate these markers with patient survival outcomes.

Main Methods:

• Prospective follow-up of 113 patients with resectable NSCLC for 8 years.
• Analysis of peritumoral B and T lymphocytes (CD20, CD43), tumor markers (CEA), and clinicopathologic factors (AJCC stage, grade, DNA ploidy, S-phase).
• Multivariate Cox proportional hazards model used to identify independent prognostic factors.

Main Results:

• AJCC stage was the strongest independent prognostic factor for survival across all NSCLC subtypes.
• Presence of peritumoral B lymphocytes (CD20+) was a positive prognostic factor, particularly in nonsquamous cell carcinomas.
• CEA was a negative prognostic factor in squamous cell carcinomas.
• DNA ploidy and high S-phase fraction were prognostic for stages II/III NSCLC, with specific associations for squamous and nonsquamous subtypes.

Conclusions:

• AJCC stage remains the most critical prognostic indicator in resectable NSCLC.
• Peritumoral B lymphocytes are associated with improved survival in nonsquamous cell lung cancers, highlighting the role of humoral immunity.
• Tumor markers and cell proliferation indices offer prognostic value in advanced stages of resectable NSCLC.